Paper36910362
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Tang X and 3 others. Afr Health Sci, 2022. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Papers, record 36910362. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36910362
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Non-alcoholic Fatty Liver Disease | Major topic |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Benzhydryl Compounds | |
| Glucosides | |
| Liver |
Source PubMed
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24322742 | Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. | Hepatobiliary Pancreat Dis Int | 2013 | https://conductscience.org/library/papers/24322742 | PubMed |
| 2 | 12111919 | Quantifying heterogeneity in a meta-analysis. | Stat Med | 2002 | https://conductscience.org/library/papers/12111919 | PubMed |
| 3 | 11003611 | Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. | Hepatology | 2000 | https://conductscience.org/library/papers/11003611 | PubMed |
| 4 | 20388946 | Therapy of nonalcoholic fatty liver disease: current status. | J Physiol Pharmacol | 2009 | https://conductscience.org/library/papers/20388946 | PubMed |
| 5 | 28303724 | Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. | Drug Metab Rev | 2017 | https://conductscience.org/library/papers/28303724 | PubMed |
| 6 | 29085205 | Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. | World J Gastroenterol | 2017 | https://conductscience.org/library/papers/29085205 | PubMed |
| 7 | 8721797 | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Control Clin Trials | 1996 | https://conductscience.org/library/papers/8721797 | PubMed |
| 8 | 33586120 | Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. | Diabetes Ther | 2021 | https://conductscience.org/library/papers/33586120 | PubMed |
| 9 | 29229391 | Hepatocyte-specific clusterin overexpression attenuates diet-induced nonalcoholic steatohepatitis. | Biochem Biophys Res Commun | 2018 | https://conductscience.org/library/papers/29229391 | PubMed |
| 10 | 30601337 | Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. | Eur J Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/30601337 | PubMed |
| 11 | 23707905 | Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. | Eur J Pharmacol | 2013 | https://conductscience.org/library/papers/23707905 | PubMed |
| 12 | 27627981 | Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. | Diabetologia | 2016 | https://conductscience.org/library/papers/27627981 | PubMed |
| 13 | 25477264 | Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. | J Hepatol | 2015 | https://conductscience.org/library/papers/25477264 | PubMed |
| 14 | 11730399 | Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. | Ann Intern Med | 2001 | https://conductscience.org/library/papers/11730399 | PubMed |
| 15 | 24185985 | NAFLD-the next global epidemic. | Nat Rev Gastroenterol Hepatol | 2013 | https://conductscience.org/library/papers/24185985 | PubMed |
| 16 | 18945255 | Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. | Aliment Pharmacol Ther | 2009 | https://conductscience.org/library/papers/18945255 | PubMed |
| 17 | 28953675 | Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. | Medicine (Baltimore) | 2017 | https://conductscience.org/library/papers/28953675 | PubMed |
| 18 | 14752836 | Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. | Hepatology | 2004 | https://conductscience.org/library/papers/14752836 | PubMed |
| 19 | 31748838 | Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. | Curr Diab Rep | 2019 | https://conductscience.org/library/papers/31748838 | PubMed |
| 20 | 15629518 | The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. | J Hepatol | 2005 | https://conductscience.org/library/papers/15629518 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42969364 | Changes in liver steatosis and liver stiffness following Empagliflozin treatment in patients with MASLD and type 2 diabetes: A single-arm pre-post study. | J Diabetes Investig | 2026 | https://conductscience.org/library/papers/42969364 | PubMed |
| 42504019 | Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis. | Endocrinol Diabetes Metab | 2026 | https://conductscience.org/library/papers/42504019 | PubMed |
| 42352264 | Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352264 | PubMed |
| 42153018 | Hepatoprotective effects of cinnamaldehyde against high-fat diet-induced liver damage. | Avicenna J Phytomed | 2026 | https://conductscience.org/library/papers/42153018 | PubMed |
| 41717349 | Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41717349 | PubMed |
| 41316185 | Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial. | BMC Endocr Disord | 2025 | https://conductscience.org/library/papers/41316185 | PubMed |
| 40589542 | Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies. | Int J Hepatol | 2025 | https://conductscience.org/library/papers/40589542 | PubMed |
| 36936142 | Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/36936142 | PubMed |
| 36910355 | Editorial I: So, who wins? It is still: NCDs 3; Infections 2. | Afr Health Sci | 2022 | https://conductscience.org/library/papers/36910355 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36910362
GET https://conductscience.org/api/papers/v1/36910362/references?page=2